Literature DB >> 8520855

Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation.

H F Hoff1, G Hoppe.   

Abstract

Structural and chemical modifications of plasma lipoproteins retained in atherosclerotic lesions, especially LDL, are a characteristic of atherogenesis. The major cholesterol-containing structures believed to be derived primarily from LDL are monomeric or aggregated native or modified LDL particles, cholesteryl ester droplets, liposomes rich in unesterified cholesterol, and ceroid-lipofuscin. They are suggested to be formed primarily from LDL by combinations of oxidation, hydrolysis by proteases and esterases, fusion of neutral lipid components, and covalent interactions between lipid and protein components of oxidized LDL in lysosomes. Although many of these structures appear to be refractory to removal by reverse cholesterol transport mechanisms, they may possess functional properties that still need to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520855     DOI: 10.1097/00041433-199510000-00012

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  4 in total

1.  Lysosomes, cholesterol and atherosclerosis.

Authors:  W Gray Jerome
Journal:  Clin Lipidol       Date:  2010-12-01

Review 2.  Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism.

Authors:  Joshua A Dubland; Gordon A Francis
Journal:  Front Cell Dev Biol       Date:  2015-02-02

Review 3.  Lysosome (Dys)function in Atherosclerosis-A Big Weight on the Shoulders of a Small Organelle.

Authors:  André R A Marques; Cristiano Ramos; Gisela Machado-Oliveira; Otília V Vieira
Journal:  Front Cell Dev Biol       Date:  2021-03-29

Review 4.  ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker.

Authors:  Eva Hurt-Camejo; Germán Camejo
Journal:  J Cardiovasc Dev Dis       Date:  2018-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.